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Objective:  To  conduct  a cost-effectiveness  analysis  of  a  universal  childhood  hepatitis  A vaccination  pro-
gram  in  Brazil.
Methods:  An  age  and time-dependent  dynamic  model  was  developed  to estimate  the  incidence  of hep-
atitis  A for  24 years.  The  analysis  was  run  separately  according  to  the pattern  of  regional  endemicity,
one  for  South  + Southeast  (low  endemicity)  and  one  for the  North  +  Northeast  + Midwest  (intermediate
endemicity).  The  decision  analysis  model  compared  universal  childhood  vaccination  with  current  pro-
gram  of vaccinating  high  risk individuals.  Epidemiologic  and  cost  estimates  were  based  on  data  from
a  nationwide  seroprevalence  survey  of  viral  hepatitis,  primary  data  collection,  National  Health  Infor-
mation  Systems  and  literature.  The  analysis  was  conducted  from  both  the health  system  and  societal
perspectives.  Costs  are  expressed  in 2008  Brazilian  currency  (Real).
Results: A  universal  immunization  program  would  have  a signiﬁcant  impact  on  disease  epidemiology
in  all  regions,  resulting  in  64%  reduction  in  the  number  of  cases  of icteric  hepatitis,  59%  reduction  in
deaths  for  the  disease  and  a 62%  decrease  of  life years  lost,  in  a national  perspective.  With a  vaccine
price  of R$16.89  (US$7.23)  per dose,  vaccination  against  hepatitis  A was  a  cost-saving  strategy  in  the
low  and  intermediate  endemicity  regions  and  in Brazil  as a  whole  from  both  health  system  and  society
perspective.  Results  were  most  sensitive  to  the  frequency  of icteric  hepatitis,  ambulatory  care  and  vaccine
costs.
Conclusions:  Universal  childhood  vaccination  program  against  hepatitis  A could  be a  cost-saving  strategy
in  all regions  of  Brazil.  These  results  are  useful  for the  Brazilian  government  for  vaccine  related  decisions
and  for  monitoring  population  impact  if  the  vaccine  is  included  in  the National  Immunization  Program.. Introduction
Although the hepatitis A vaccine is effective, safe and available
ince the 1990s, routine childhood immunization against hepatitis
 still is an underused policy.
∗ Corresponding author at: Rua José Maria Lisboa, 695 ap. 91, São Paulo, SP 01423
01,  Brazil. Tel.: +55 11 2661 7517; fax: +55 11 2661 7517.
E-mail  address: anasartori@gmail.com (A.M.C. Sartori).
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In high endemic areas, hepatitis A occurs early in childhood and
most infections are asymptomatic. Improvement of the sanitary
conditions leads to a shift of the age groups affected by hepatitis
A, with increasing incidence in older age groups and higher fre-
quency of icteric and serious disease, enhancing the importance
of hepatitis A as a public health problem. Higher risk of outbreaks
with common source also occurs in areas in transition from high to
Open access under the Elsevier OA license.intermediate/low endemicity [1].
The World Health Organization (WHO) recommends univer-
sal vaccination against hepatitis A in countries with intermediate
endemicity [1]. Israel, USA and Argentina have implemented
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niversal childhood vaccination programs against hepatitis A with
reat impact on the disease epidemiology [2–6].
Brazil is undergoing epidemiological transition, presenting two
istinct epidemiological patterns: the North, Northeast and Mid-
est regions with intermediate endemicity of hepatitis A, and the
outh and Southeast regions with low endemicity [7–9]. Hepatitis
 vaccine is available at the Brazilian public health system (Sistema
nico de Saúde, SUS) only for patients at risk of serious illness, such
s those with chronic liver disease, coagulopathy, hemoglobinopa-
hy, cystic ﬁbrosis, persons aged ≤13 years with HIV infection,
arriers of hepatitis B and C virus, immunocompromised hosts,
andidates for donor and transplant organs. The vaccine is also
vailable at the private health system. This strategy results in very
ow vaccine coverage: <1% of children aged 1–4 years received the
accine in 2009. According to WHO  criteria, the country should con-
ider the introduction of universal vaccination against hepatitis A
1].
We  conducted a cost-effectiveness analysis of a universal child-
ood hepatitis A vaccination program in Brazil. Since hepatitis A
eroprevalence, disease treatment costs and indirect costs differ
hroughout the country, cost-effectiveness of vaccination may  also
iffer. So, the analysis was run separately according to the regional
ndemic context.
.  Methods
Two strategies were compared: universal childhood hepatitis
 vaccination program in the second year of life and the current
trategy (vaccination of high risk persons).
.1. Model structure and parameterization
An age and time-dependent susceptible – infected/infectious –
ecovered – vaccinated (SIRV) compartmental dynamic model of
epatitis A transmission was developed to estimate the incidence
f the disease for a period of 30 years (Appendix A) [10,11]. The
odel was based on data from a nationwide population survey of
eroprevalence of hepatitis, conducted from 2004 to 2009, which
nvolved persons aged 5–69 years, in the 27 Brazilian state capitals.
t showed an area of intermediate endemicity of hepatitis A – the
orth, Northeast, and Midwest regions, where 32.8%, 52.9% and
3.2% of children and adolescents aged 5–9, 10–14 and 15–19 years
ad anti-hepatitis A antibodies, and an area of low endemicity –
he South and Southeast regions, where 19.8%, 30.3% and 43.7%
f children and adolescents of the same age had anti-hepatitis A
ntibodies [7–9].
The  model incorporated a variable force of infection accounting
or herd effects of a universal immunization program. Demographic
ata were obtained from Brazilian National Institute of Statis-
ics (Instituto Brasileiro de Geograﬁa e Estatística, IBGE) [12]. The
ynamic model predicted the numbers of hepatitis A infections by
ge and year for the whole Brazilian population, with the current
trategy and the impact of a universal childhood immunization
rogram. The analysis was run separately combining the North,
ortheast and Midwest macro-regions, from now on called “North”
rea, and for the South and Southeast, from now on called “South”
rea.
A decision analysis model built in Microsoft Excel was  used to
stimate health services utilization and costs associated to hepatitis
 by age group and region of residence.
The analysis was conducted using the health system perspec-ive, including all direct medical costs (medical visits, diagnostics
ests, medications and hospitalizations), and the societal perspec-
ive, incorporating nonmedical and productivity costs. The out-
omes measured are cases averted, deaths averted and life-years 30 (2012) 7489– 7497
saved  (LYS). The time horizon of the economic analyses was  24
years. Future costs and outcomes were discounted at 5% [13].
2.2.  Epidemiological estimates and health services utilization for
hepatitis A
Table  1 summarizes epidemiological estimates. The age-speciﬁc
proportions of icteric cases were taken from a previous study
reporting the probability of developing jaundice during acute hep-
atitis A [14]. The number of hospitalizations for hepatitis A in
the Public Health System in 2008 was retrieved from the Hospi-
talization Information System (Sistema de Informac¸ ão Hospitalar,
SIH/SUS). Because SIH/SUS registers only data for the public sys-
tem, we  used data from a nationwide household survey (Pesquisa
Nacional por Amostra de Domicílios, PNAD), to estimate hospital-
izations at the private sector [15]. PNAD-2008 showed that 74.9%
of overall hospitalizations for clinical reasons were ﬁnanced by
SUS. From the estimated total number of hospitalizations and the
number of icteric cases (estimated from the dynamic model), we
estimated the hospitalization rates, by age and region of residence,
for the base year.
The  proportions of transplantation among hospitalized cases
were based on data from the National Agency of Transplantation
showing that 46% of persons who enter the transplant list for acute
liver failure undergo liver transplantation. A prospective multicen-
ter study conducted in Argentina, Brazil, Chile, Colombia, Costa Rica
and Mexico, also showed 46% of patients with acute liver failure for
hepatitis A were transplanted [16]. Estimates of liver failure among
hospitalized hepatitis A cases, by age and region of residence, were
based on the average annual number of fulminant hepatitis A cases
reported to Notiﬁable Diseases Information System (Sistema de
Informac¸ ão de Agravos de Notiﬁcac¸ ão, SINAN) [17] and the esti-
mated total hospitalizations for hepatitis A. Hospital case-fatality
rates before transplantation were taken from the SIH/SUS. Sur-
vival of 56.7% in the ﬁrst year after transplantation was based
on data from the State of São Paulo System for Transplantation
[18].
2.3. Vaccination strategies, effective coverage and costs
The  universal vaccination program assumed two  vaccine doses
administered in the second year of life. The ﬁrst dose may  be admin-
istered simultaneously with other vaccines already included in the
childhood immunization schedule (at 12 or 15 months), but an
additional visit is needed to administer the second dose of the
vaccine, six months after the ﬁrst dose. The current strategy was
assumed to have no effects on transmission of hepatitis A, consid-
ering its low coverage.
In  the base case, we assumed effective coverage of 85% (94%
vaccine efﬁcacy and 90% vaccination coverage) and wastage rate of
5% (Table 1) [1,19]. Waning immunity was not considered in the
model.
The costs of the universal vaccination program included cost of
vaccine dose and cost of administration. Vaccine costs were based
on the price paid by the Brazilian National Immunization Program
in 2008 (R$16.89 = US$7.23) plus an estimated administrative cost
of R$2.33 (US$1) [20] (Table 2). As the second dose of the vaccine
requires a new visit to the health center, transportation costs of
this new visit were included in the model when the analysis was
conducted from the society perspective.Health care utilization and costs of adverse events following
hepatitis A vaccination were not considered, since they are rare
and mild, and the associated costs may  be considered insigniﬁcant
[21].
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Table  1
Summary of epidemiological and vaccine estimates by region analysis.
Estimates Base case Sensitivity analysis Source
North South National
All regions
Epidemiological
Proportion of icteric cases among infectious (%)
age-group—years
[12]
<1  7.20 7.20 7.20 −50 to −90
1–4  7.20 7.20 7.20 −50 to −90
5–9  37.10 37.10 37.10 −50 to −90
10–19  70.70 70.70 70.70 −50 to −90
20–79  85.20 85.20 85.20 −50 to −90
Proportion  of hospitalization among icteric cases
(%)
[Authors assumptions
based  on SIH/SUS and 13]
<1 2.38 0.75 1.83 −50 to −75
1–4  1.00 0.74 0.91 −50 to −75
5–9  0.22 0.13 0.18 −50 to −75
10–14  0.09 0.05 0.07 −50 to −75
15–19  0.12 0.06 0.09 −50 to −75
20–29  0.16 0.06 0.09 −50 to −75
30–39  0.29 0.11 0.15 −50 to −75
40–49  0.87 0.25 0.38 −50 to −75
50–59  2.31 0.45 0.77 −50 to −75
60–69  3.33 1.04 1.47 −50 to −75
70–79  19.38 2.56 4.87 −50 to −75
Case-fatality  rates among hospitalized cases before
liver  transplantation (%)
[Authors assumptions
based  on SIH/SUS]
<1  0.00 0.00 0.00
1–4  0.41 0.65 0.47
5–9  0.55 0.42 0.51
10–14  0.55 0.42 0.51
15–19  0.61 0.79 0.67
20–29  0.99 1.11 1.03
30–39  1.45 3.92 2.54
40–49  4.76 4.87 4.82
50–59  6.16 8.25 7.25
60–69  4.02 10.30 6.87
70–79  8.41 12.06 9.81
Proportion  of liver transplant among hospitalized
cases (%)
[Authors assumption based
on  14, 16]
<1–14  0.441 0.469 0.451 −50
15–39  0.142 0.212 0.183 −50
40–79  0.000 0.042 0.021 −50
Survival  in the ﬁrst year post-transplantation (%) 56.7% 56.7 56.7% – [15]
Vaccine
Efﬁcacy  (%) 94 94 94 90–95 [1]
Coverage  (%) 90 90 90 84–95 [DATASUS/PNI]
Effective  coverage (%) 85 85 85 75–90
t
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To estimate the annual cost of the current strategy (vaccina-
ion of high risk persons), we considered the total vaccine doses
157,611) administered in Brazil in 2008.
.4. Health care costs
Health  care cost estimates, summarized in Table 2, were calcu-
ated by age group and area of residence.
Direct medical costs were estimated for outpatient care,
npatient treatment, liver transplantation and follow up post trans-
lantation. The standard outpatient care for acute hepatitis A was
ased on expert opinion. The cost of health service utilization
n public outpatient facilities was valued using the SUS proce-
ures reimbursement prices in 2008, available in the Public Health
nformation System (Sistema de Gerenciamento da Tabela de Pro-
edimentos, Medicamentos e OPM do SUS, SIGTAP) [22]. The costs
f cases treated in the private sector were estimated based on the
008 values recommended by the Brazilian Medical Association.
We  assumed that all hospitalized cases of hepatitis A would also
ave outpatient care. Thus, the costs of hospital treatment include5 – [Authors assumption based
on  17]
the  costs of hospitalization itself plus the costs of the outpatient
care (medical visits + diagnostic tests). Since values for hospitaliza-
tion in the private sector were not available, we  assumed the same
values of the public system, taken from SIH/SUS.
As the Brazilian public health system is responsible for most
transplantation, we adopted the average cost of hospitalization for
liver transplantation in the SUS for both systems.
Due to lack of data for the costs of outpatient follow up post
transplantation, primary data was  collected in the Digestive Sys-
tem Organ Transplantation Service of the Hospital das Clinicas, the
academic hospital of the University of Sao Paulo School of Medicine,
in Sao Paulo, Brazil. The direct costs of transporting patients to
receive care were included when the analysis was performed from
the society perspective.
Indirect  costs refer to lost productivity due to hepatitis A by the
patient or caregivers (we  assumed the mother) of children aged <15
years. We  used the human capital approach to calculate indirect
costs. Lost productivity was  calculated by multiplying the esti-
mated number of working days lost by the national average wage
for women. We assumed mean duration of 15 days for hepatitis
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Table  2
Summary of input cost parameters by region analysis (in 2008 Brazilian currency, Real, R$2.33 = US$1).
Costsa parameters Base case Sensitivity
analysis
Source
North South National All regions
Health system
perspective
Society
perspective
Health  care system
perspective
Society
perspective
Health  care system
perspective
Society
perspective
Vaccine dose 16.89 16.89 16.89 16.89 16.89 16.89 +50 to +150% [CGPNI]
Administration 2.33 2.33 2.33 2.33 2.33 2.33 – [17]
Outpatient  treatmenta [Authors
assumptions]
<1  year 103.53 405.65 120.21 468.75 111.70 417.19 −50 to −75%
1–4  years 103.53 405.65 120.21 468.75 111.70 417.19 −50 to −75%
5–9  years 97.26 399.37 112.32 460.87 104.69 410.19 −50 to −75%
10–14  years 101.72 411.36 111.17 467.83 104.69 417.71 −50 to −75%
15–19  years 171.36 270.64 189.70 334.58 179.29 298.04 −50 to −75%
20–29  years 181.09 468.18 202.79 600.99 189.50 524.76 −50 to −75%
30–39  years 181.87 601.03 199.57 749.02 189.95 667.33 −50 to −75%
40–49  years 182.31 675.53 188.75 787.82 188.75 733.19 −50 to −75%
50–59  years 179.61 636.33 188.86 714.42 184.60 677.28 −50 to −75%
60–69  years 176.95 427.57 190.16 494.57 184.83 463.58 −50 to −75%
70–79  years 185.30 284.52 201.27 311.53 194.04 298.69 −50 to −75%
Inpatient  treatmentb [SIH/SUS]
<1  year 326.15 1141.89 370.79 1372.06 337.85 1169.26 –
1–4  years 317.14 1133.27 435.00 1384.30 352.30 1179.34 –
5–9  years 313.79 1124.81 331.11 1264.98 321.82 1141.51 –
10–14  years 312.00 1132.11 381.99 1331.24 334.64 1165.03 –
15–19  years 389.29 656.18 410.19 796.90 398.08 716.10 –
20–29  years 388.77 1152.79 419.92 1484.18 400.69 1293.77 –
30–39  years 393.11 1524.55 454.56 1953.61 422.17 1716.80 –
40–49  years 401.86 1744.76 513.21 2174.62 458.63 1957.92 –
50–59  years 491.85 1728.62 484.64 2026.76 489.09 1875.48 –
60–69  years 398.28 1072.21 713.65 1587.32 569.83 1346.36 –
70–79  years 425.78 698.22 788.12 1103.57 573.78 865.71 –
Transplantationc [DATASUS]
<39  years 53,703.16 61,183.45 53,703.16 62,402.86 53,703.16 65,611.34 −50%
40–49  years 53,703.16 55,882.38 53,703.16 57,028.67 53,703.16 67,309.46 −50%
50–59  years 53,703.16 60,759.75 53,703.16 63,614.45 53,703.16 65,998.77 −50%
60–69  years 53,703.16 64,087.78 53,703.16 67,452.36 53,703.16 60,581.87 −50%
70–79  years 53,703.16 65,954.20 53,703.16 68,711.88 53,703.16 56,173.70 −50%
Follow  up post transplantationd
1 year 34,364.24
2  years 15,923.79
3  years 9889.13
4 years 7436.03
5–23 years 5761.42
Discount rate 0 +5%, +10%
a Outpatient treatment costs include two  medical visits and diagnostic tests, in the health care system perspective. In the society perspective, they also include transportation
and indirect costs related to lost productivity from the patient and caregivers of children under-15 years of age.
b Inpatient treatment costs include hospitalization in the health care system perspective. In the society perspective, they also include transportation and indirect costs
related to lost productivity from the patient and caregivers of children under-15 years of age.
c Transplantation costs include the procedure cost, in the health care system perspective. In the society perspective, they also include transportation and indirect costs
related to lost productivity from the patient and caregivers of children under-15 years of age.
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erspectives.
 outpatients [23]. For inpatients, estimates of duration of disease
ere based on the speciﬁc average hospital stay by age group and
egion of residence, retrieved from SIH/SUS, to which we  added
0 days before the admission and 10 days after the discharge. The
uration of inpatient disease ranged from 24 to 30 days.
.5.  Sensitivity analysis
Because  of uncertainty in our baseline estimates, we  conducted
nivariate and bivariate sensitivity analysis on key parameters,
uch as the frequency of icteric cases, rates of hospitalization, pro-
ortions of liver transplantation, vaccine price and outpatient care
osts. A reduction of 1% a year in the incidence of hepatitis A due
o improvement in sanitary conditions was also considered in the
ensitivity analyzes.ts, medical visits, and hospitalization. The same value was used in both regions and
3. Results
3.1. Model estimates
Hepatitis  A seroprevalence data from the nationwide pop-
ulation survey [7–9], provided the following ﬁtting parame-
ters: k1 = (0.01762 ± 0.00096) yr−2 and k2 = (0.0699 ± 0.0048) yr−1
for the “North” area and k1 = (0.00815 ± 0.00018) yr−2 and
k2 = (0.0485 ± 0.0031) yr−1 for the “South” area. Those parameters
were used to estimate the force of infection for each area (Fig. 1).
We ran a simulation of the SIRV model without vaccination to
estimate the proportion of infectious  (a, t) (Appendix A). This
proportion was then converted to number of new infections per
100,000 inhabitants (Fig. 2). The next step was simulating different
vaccination scenarios: with 75% effective coverage (vaccine efﬁcacy
of 90% and coverage rate of 84%), 85% effective coverage (94% and
A.M.C. Sartori et al. / Vaccine
Fig. 1. Seroprevalence data, the corresponding ﬁtted curve (dashed line and left-
hand scale), and the age-dependent force of infection (thick line and right-hand
scale)  of hepatitis A in “North” (North + Northeast + Midwest regions) and “South”
(South  + Southeast regions) areas, Brazil, 2008.
0 10 20 30
0.0
0.5
1.0
1.5
0 10 20 30
0.0
0.5
1.0
1.5
South
N
e
w
 i
n
fe
c
ti
o
n
s
 (
m
ill
io
n
s
)
Years post vaccine introduction
no vaccin ati on
p=75 %
p=85 %
p=90 %
no vaccin ati on
p=75 %
p=85 %
p=90 %
North
Fig. 2. Number of new hepatitis A infections estimated by the dynamic model in
the North and South areas in the absence of vaccination and for three different
effective  coverage (vaccine efﬁcacy ×vaccination coverage): 90% (95% × 95%); 85%
(94% ×90%), and 75% (90% × 84%). 30 (2012) 7489– 7497 7493
90%), and 90% effective coverage (95% and 95%) for both areas sep-
arately. These proportions were also converted to number of new
infections per 100,000 inhabitants (Fig. 2). The numbers of new
infections in both areas by age and year of occurrence were added
up to run the national analysis.
3.2.  Disease impact and cost-effectiveness ratios
Tables 3 and 4 summarize disease impact, costs and cost-
effectiveness ratios of the analyses of the two areas and the national.
Under the base case assumptions (two dose vaccination schedule,
vaccine efﬁcacy of 94% and coverage of 90%) a universal childhood
immunization program would have a signiﬁcant impact on dis-
ease epidemiology, resulting in 64% reduction in the number of
icteric cases, 59% reduction in deaths and 62% decrease of life years
lost, in a nationwide perspective. The reduction of the icteric cases
would be slightly larger in the “North” (68%) than in the “South”
(61%), as well as the reduction in deaths, “North” (65%) and “South”
(57%). The universal program brings incremental costs that are
compensated for lower disease treatment costs (Table 3). Hepatitis
A vaccination was a cost-saving (more effective and less expensive)
strategy in the “North” (intermediate endemicity), in the “South”
(low endemicity), and in Brazil as a whole from both health system
and society perspective, without and with 5% discount of cost and
beneﬁts.
3.3. Sensitivity analysis
Universal  childhood hepatitis A vaccination program was  a cost-
effective strategy in most variations of the key estimates (Table 4).
The incremental cost-effectiveness ratios (ICERs) were more sen-
sible to variations in the proportion of icteric cases, vaccine costs
and outpatient care costs. Reduction of 1% a year in the incidence
of the infection due to improvement in sanitary conditions did not
impact on the ICERs. Variations in hospital and liver transplanta-
tion costs had no impact on the ICER either. Despite their high costs,
these procedures are rare, and the large number of outpatients had
greater impact on the ICER.
4.  Discussion
Results showed that a universal childhood vaccination program
against hepatitis A would have an important impact on the epi-
demiology of the disease.
The  incremental cost-effectiveness ratios (ICERs) showed our
base case scenario of universal vaccination as a cost-saving strat-
egy in the intermediate and low endemic areas, and in Brazil as a
whole, from both health system and society perspective. Among
the cost-effectiveness studies of new vaccines (rotavirus, varicella,
pneumococcal conjugate, and meningococcal C conjugate) we  con-
ducted for the Brazilian Ministry of Health, only hepatitis A vaccine
proved to be a cost-saving intervention [11,24–26].
In the sensitivity analysis, results were more sensitive to vari-
ations in the proportions of icteric infection, vaccine costs and
outpatient care costs (Table 4). However, only with large vari-
ations in these parameters, universal vaccination becomes not
cost-effective in both perspectives. Since there is no Brazilian
standard of cost-effectiveness, we use WHO  criteria, that considers
an intervention “very cost-effective” when the cost of averting one
disability-adjusted life-year (DALY) is less than the gross domestic
product (GDP) per capita; an intervention is considered “cost-
effective” if the cost per DALY averted is from 1 to 3 times the GDP
per capita; and an intervention is “not cost-effective” if the cost
per DALY averted is >3 times the GDP per capita. 2008 Brazilian
GDP = R$15,240 (US$6541).
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Table  3
Predicted outcomes under two  vaccination strategies by area analyzed.
Outcomes Base case
North South National
All regions
Current strategya Universal vaccination Current strategya Universal vaccination Current strategya Universal vaccination
Disease impact
Number of icteric cases 19,362,612 6,242,236 25,566,782 10,095,236 44,929,394 16,337,472
Number of avoided cases 13,120,376 15,471,546 28,591,922
Reduction  in the number
of  icteric cases (%)
68 61 64
Number  of deaths 819 288 1040 449 1787 732
Number  of avoided
deaths
532 591 1055
Reduction  in the number
of  deaths (%)
65 57 59
Number  of life years lost 21,217 6954 21,669 9010 42,275 16,122
Number  of life years
gained
14,263 12,659 26,153
Reduction  in the number
of  life years lost (%)
67 58 62
Costsb Society perspective
Disease treatment costc 7,994,666,912 4,146,691,719 13,863,427,939 7,082,620,447 20,858,463,895 10,793,846,069
Treatment  cost avoided 3,847,975,193 6,780,807,492 10,064,617,826
Reduction  in the
treatment  costs (%)
48 49 48
Intervention  costd 13,449,071 1,563,205,826 62,496,666 1,512,334,409 75,945,737 3,055,278,919
Incremental cost of
universal  vaccination
1,539,756,756 1,449,837,743 2,979,333,182
a Current strategy: vaccination of high risk group.
b In 2008 Brazilian currency (real), R$2.33 = US$1.
c In the perspective of society, it includes costs of hospital treatment, transplantation, follow up post transplantation, medical visits, diagnostic tests and medication, family
transportation costs and indirect costs (lost productivity of the caregiver and patient).
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ssuming 94% of vaccine coverage and that all children that initiate vaccination sch
Hepatitis A seroprevalence data used in the dynamic model
as taken from a nationwide population survey conducted in all
tate capitals covering all regions, the best available evidence for
razil. Data from state capitals were generalized to the entire coun-
ry. Possible differences in seroprevalence of hepatitis A between
he capitals, usually with better sanitary conditions, and smaller
owns, villages and rural areas were not considered in the model.
owever, 2010 Brazilian census showed that 84% of Brazilian
opulation lives in urban areas. A National Sanitation Survey, con-
ucted in 2008, showed that safe water supply reaches 99.4%
f Brazilian municipalities, solid waste management (including
cavenging and garbage collection) 100%, and sewage collection
5.2% [27].
The  proportion of icteric cases and the components and costs
f outpatient care have a large impact on the ICER, as shown by
ensitivity analysis (Table 4).
The numbers of icteric hepatitis A cases are difﬁcult to estimate
ue to variations in clinical assessment and underreporting. The
roportion of icteric cases among all infections is not well known.
iterature review found only one study reporting the frequency
f jaundice by age group [14], which was also used in economic
tudies of hepatitis A vaccine in Argentina and Chile [28–31]. The
ensitivity analysis showed the proportion of icteric cases impact
he ICER; however, even with a reduction of 50% of the base case
alues, universal vaccination remained a cost-saving strategy in the
ociety perspective and was cost-effective in the health system per-
pective. A reduction of 75% over the base case makes universal
accination not cost-effective from the health system perspective,
lthough cost-effective in the North and still cost-saving in South
nd in the whole country from the society perspective. Only with
xtreme values (90% reduction over the base case), very unlikely,
niversal vaccination becomes not cost-effective from the society
erspective (Table 4).of vaccine, administration cost (R$2.33 = US$1 per dose) and 5% of vaccine wastage,
eceived two  recommended doses.
Hepatitis A is mainly treated in outpatient settings. Data on
health services utilization and procedures of the outpatients care
are quite scarce in Brazil. The ambulatory (SIA/SUS) and primary
health care (SIAB/SUS) public health information systems do not
provide data according to diagnosis. We established a “minimum
care package” of outpatients care and costs, a decision which
may have underestimated these costs, particularly in the special-
ized clinics and in the private sector. Sensitivity analysis showed
that outpatient costs impact the ICER. With a 50% reduction in
outpatient costs, the program continued cost-saving from soci-
ety perspective, and cost-effective from health system perspective.
Only with reduction of 75% of outpatient costs (very unlikely)
the intervention became not cost effective in the health sys-
tem perspective, although it became cost-effective in North and
remained cost-saving in South and National from society perspec-
tive (Table 4).
The  vaccine cost also has great impact on the ICER. The price
of R$24.35 (US$10.45) per dose (50% higher of our base case), paid
by the Ministry of Health in 2010, makes the universal childhood
vaccination program cost-effective in North from the perspective
of the health system, but it remained a cost-saving strategy in the
perspective of the Society; and in South and National in both per-
spectives.
Waning immunity has not been considered in our model. There
is evidence that the inactivated hepatitis A vaccine provides protec-
tion for up to 14 years, as deﬁned by currently accepted correlates
of protection [32]. Mathematical models suggested duration of pro-
tection for 50 years, with 95% of vaccinees keeping protection
for more than 35 years, if the cut-off of protection is estab-
lished at 10 mIU/ml, or for more than 30 years if the cut-off is
established at 20 mIU/ml [33]. This is longer than the temporal
horizon of our study (24 years). Furthermore, herd protection has
been demonstrated for hepatitis A vaccination, with reduction in
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Table  4
Sensitivity analysis by perspective and area analyzed.
Sensitivity analysis Cost per life year saveda
North South National
All regions
Health care system
perspective
Society
perspective
Health care system
perspective
Society
perspective
Health care system
perspective
Society
perspective
Univariate
Reduction in the incidence of hepatitis A infection due to improvement in sanitary conditions
Low  (−1% per year) <0 <0 <0 <0 <0 <0
Base  case <0 <0 <0 <0 <0 <0
%  of symptomatic infection
Extremely  low (−90%) 85,294 68,350 82,479 48,012 86,689 62,354
Much  lower (−80%) 72,938 30,779 62,122 <0 70,342 12,667
Very low (−75%) 66,761 11,993 51,943 <0 62,168 <0
Low (−50%) 35,872 <0 1050 <0 21,299 <0
Base  case <0 <0 <0 <0 <0 <0
%  of hospitalizationb
Very low (−75%) <0 <0 <0 <0 <0 <0
Low  (−50%) <0 <0 <0 <0 <0 <0
Base  case <0 <0 <0 <0 <0 <0
%  of transplantationb
Very low (−75%) <0 <0 <0 <0 <0 <0
Low  (−50%) <0 <0 <0 <0 <0 <0
Base  case <0 <0 <0 <0 <0 <0
Vaccine  price per dose
Base  case <0 <0 <0 <0 <0 <0
R$24.35c (+50%) 12,543 <0 <0 <0 <0 <0
Very  high (+100%) 61,250 <0 26,882 <0 31,385 <0
Extremely  high (+150%) 148,405 <0 118,395 <0 123,209 <0
Outpatient  costs
Very  low (−75%) 66,761 11,993 60,970 <0 62,168 <0
Low  (−50%) 35,872 <0 19,103 <0 21,299 <0
Base  case <0 <0 <0 <0 <0 <0
Discount  rated
Base case 0% <0 <0 <0 <0 <0 <0
3% <0 <0 <0 <0 <0 <0
5%  <0 <0 <0 <0 <0 <0
10% <0  <0 <0 <0 <0 <0
Bivariate
Effective  coveragee
Low (75%) <0 <0 <0 <0 <0 <0
Base  case (85%) <0 <0 <0 <0 <0 <0
High  (90%) <0 <0 <0 <0 <0 <0
Costs  of transplantation and follow-up post-transplantation
Low (−50%) <0 <0 <0 <0 <0 <0
Base  case <0 <0 <0 <0 <0 <0
a In 2008 Brazilian currency (real) R$2.33 = US$1.
b The rates of all age groups are varied simultaneously.
c Current vaccine price.
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e Effective coverage is the product of multiplication of two factors (vaccine efﬁca
0% (95% and 95%).
isease incidence in non-vaccinated groups after the introduction
f universal vaccination in children [2,5]. Even if the antibodies
ecreases, herd protection may  keep transmission of hepatitis A
nder control. However, there is no data in the literature on the
mpact of hepatitis A universal vaccination program for such long
ime. The oldest programs have been implemented in the late 1990s
2,5]. In case of decline of protection over time, a shift in the age of
ew infections to older age groups, which may  have more severe
llness, may  occur. In other economic studies, varying the rates
f waning immunity in the sensitivity analysis had no impact on
ost-effectiveness ratio [34].
The hepatitis A vaccine is commercially available in single-dose
ials, which reduces waste, but it occupies more space in the cold
hain than vaccines presented in multi-dose vials. Additionally,
ue to recent introductions into the national childhood immu-
ization schedule, of the 10-valent pneumococcal conjugate and
eningococcal C conjugate vaccines, both also available in single
ose vials, the cold chain is currently already under great stress.d vaccine coverage). Low: 75% (84% and 90%). Base case: 85% (90% and 94%). High:
The  introduction of a new vaccine in the program requires a pre-
liminary assessment of the cold chain capacity and the required
adjustments and investments, which were not considered in our
analyses.
The ﬁrst dose of the vaccine was  assumed to be adminis-
tered simultaneously to other vaccines already incorporated by the
National Immunization Program and would not require a new visit
to the Vaccination Clinic, but the second dose would require a spe-
ciﬁc visit. The transportation cost to the health center to receive
the second dose of the vaccine was considered when the analysis
is carried out from the society perspective. Indirect costs related to
the vaccination process were not included in the analyses consid-
ering that the Brazilian Ministry of Health provides standing orders
for routine children vaccination, which is administered by nurses in
health centers near the families’ home; a pre-vaccination medical
visit is not required and not usual; and the vaccination process is
quick. Therefore, parents do not usually lose a workday to vaccinate
their children.
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Most economic studies of hepatitis A vaccine showed favorable
ost-effectiveness results. Universal childhood vaccination against
epatitis A was shown a cost-saving strategy in areas of higher
ncidence of disease in Argentina [29] and USA [35,36]. In China,
he immunization program has proved to be cost-saving in areas of
owest, low, intermediate and high endemicity of hepatitis A [37].
In  other contexts, the parameters that mostly inﬂuenced the
esults of economic evaluations were administration cost and cost
er vaccine dose, followed by the incidence of disease and medical
osts, as in this study.
The  regional analysis showed some differences in the impact
f a universal hepatitis A vaccination program in Brazil. Greater
eduction in the number of icteric cases and deaths are expected in
he “North” area. The results of the South model were more robust
han the North and national models.
Although the producers of the hepatitis A vaccine recommend
wo-dose schedule to ensure long-term efﬁcacy, immunogenicity
tudies have shown that >90% of children have protective anti-
ody titers after a single dose. There is evidence of seroprotection
or up to 10 years after a single dose of hepatitis A vaccine [38].
rgentina observed a signiﬁcant reduction in the incidence (80%)
nd hospitalizations (88%) for hepatitis A after introducing a single
ose of the vaccine in routine immunization of 12-month children
ith high vaccination coverage (95%) [5,6]. Six years after imple-
enting the single-dose program, no cases of hepatitis A have been
bserved in vaccinees, although hepatitis A continued occurring in
on-vaccinated persons [38]. The WHO  Strategic Advisory Group
f Experts has recently concluded that National Immunization Pro-
rams may  consider the introduction of a single-dose of hepatitis A
n their immunization schedules [39]. A single-dose schedule saves
osts with the vaccine, being attractive particularly for countries
ith economic constraints.
Regardless  of schedule used, the incorporation of hepatitis A
accine into the routine must be accompanied by intensiﬁcation of
urveillance and monitoring program impact.
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ppendix  A.
We  have implemented an age- and time-dependent compart-
ental model, dividing the population into four compartments:
usceptible, infected/infectious, recovered from natural infection,
nd vaccinated individuals (SIRV model). A full description of the
IRV model and the parameters estimation procedure may  be found
lsewhere [11]. We  brieﬂy describe below the main steps of the
odeling approach.
From  the model, we have estimated the force of infection, (a, t),
he per capita rate at which individuals with age a acquire infection
t time t. The calculation of the force of infection depends on a
ontact rate function ˇ(a, a′), given by the number of potentially
nfectious contacts a person with age between a and a + da makes
ith all persons with age between a′ and a′ + da′ per unit time.
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We  assumed a constant vaccination rate, related to a given pro-
portion p of the population covered by the routine immunization
program, delivered between 1 and 2 years of age.
An estimate of the function S+(a), the proportion of seroposi-
tive individuals for hepatitis A with age a, resulted from ﬁtting the
serological data to [40]:
S+(a) = 1 − exp
{
k1
k22
[(k2a + 1)e−k2a − 1]
}
, (1)
where  k1 and k2 are the ﬁtting parameters, estimated by the max-
imum likelihood method for the North and South areas.
In  the absence of vaccination, the force of infection 0(a) was
estimated from the seroprevalence data by the equation below
[11]:
0(a) = k1ae−k2a. (2)
For  the contact function, we have chosen the following form
[10]:
ˇ(a, a′) = b1(a + a′)e−b2(a+a
′)e−(a
′−a)2/[b3+b4(a+a′)]2ea, (3)
where   is the mortality rate, and b1, b2, b3 and b4 are parameters
to be determined.
The  parameters of the contact function ˇ(a, a′) were estimated
so that the resulting force of infection (a), in the absence of
vaccination, agreed with 0(a) given by Eq. (2). A more detailed
description of the numerical solution may  be found in another
publication [10].
The  mortality rate was estimated as the inverse of the life
expectancy at birth, taken as  = 0.0135 yr−1 (life expectancy of
74 years) and  = 0.0139 yr−1 (life expectancy of 72 years) for the
South and North areas, respectively. The recovery rate  was taken
to be 8.1 yr−1, corresponding to an infectious period of 45 days.
The proportion of new infections,  (a, t), was estimated by
  (a, t) = r(a, t) − r(a − t,  t − t) (4)
where  r(a, t) is the proportion of recovered individuals with age
a at time t, and t  is a time interval. In Eq. (4), we assumed that
the increment in the proportion of recovered individuals, r(a, t),
during a time interval t  is directly related to the proportion of
new infections.
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